Vihann Kong

Applied BioMath LLC operates as a biotechnology company. The firm uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. It specializes in mechanistic PK/PD, quantitative decision making, risk assessments, predict optimal drug properties for lead gen or clinical candidate selection, phase 1 and phase 2 support and analysis, technical due diligence. The company was founded by John M. Burke, Joshua Apgar and Andrew Sutherland in 2013 and is headquartered in Concord, MA.

Applied BioMath LLC operates as a biotechnology company. The firm uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. It specializes in mechanistic PK/PD, quantitative decision making, risk assessments, predict optimal drug properties for lead gen or clinical candidate selection, phase 1 and phase 2 support and analysis, technical due diligence. The company was founded by John M. Burke, Joshua Apgar and Andrew Sutherland in 2013 and is headquartered in Concord, MA.

Applied BioMath LLC operates as a biotechnology company. The firm uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. It specializes in mechanistic PK/PD, quantitative decision making, risk assessments, predict optimal drug properties for lead gen or clinical candidate selection, phase 1 and phase 2 support and analysis, technical due diligence. The company was founded by John M. Burke, Joshua Apgar and Andrew Sutherland in 2013 and is headquartered in Concord, MA.

Applied BioMath LLC operates as a biotechnology company. The firm uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. It specializes in mechanistic PK/PD, quantitative decision making, risk assessments, predict optimal drug properties for lead gen or clinical candidate selection, phase 1 and phase 2 support and analysis, technical due diligence. The company was founded by John M. Burke, Joshua Apgar and Andrew Sutherland in 2013 and is headquartered in Concord, MA.